Indivior, the FTSE 250-listed speciality pharmaceutical group, is rumoured to be "closing in" on Opiant Pharmaceuticals, a US-listed addicition treatment developer.
This is paywall protected Betaville Intelligence content. You need to purchase a subscription to access this content. Or get in touch with subscription sales at [email protected] to find out about the different subscription packages on offer.
